This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
fgfr
FGFR
Receptor tyrosine kinase family (FGFR1-4) binding FGF ligands → RAS-MAPK and PI3K-AKT → proliferation, angiogenesis, and differentiation. Amplified in breast/gastric, mutated in bladder/cholangiocarcinoma; erdafitinib (FGFR3) and pemigatinib (FGFR1-3) are approved inhibitors.
Entry Metadata
| Field | Value |
|---|---|
| ID | fgfr |
| Name | FGFR |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338-348. · PubMed 31340094
- Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma. Lancet Oncol. 2020;21(5):671-684. · PubMed 32203698